CPI-613 safe and somewhat efficacious for patients with leukemia
the ONA take:
According to a new study published in the journal Clinical Cancer Research, a phase 1 study has demonstrated that a novel investigational drug, known as CPI-613, was safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia. In the study, researchers enrolled 26 patients with relapsed or refractory hematological cancers and administered CPI-613 on days 1 and 4 weekly for 3 weeks of a 28-day cycle.
Of 21 evaluable patients, 29% experienced some benefit from the treatment. One patient achieved a complete response and that patient's remission has lasted over 3 years. Another patient achieved a partial response with a remission that lasted greater than 2 years.
CPI-613 is the first drug to inhibit the production of energy in the mitochondria of cancer cells, thereby inhibiting proliferation and damage repair from chemotherapy. The drug is currently being studied in phase 2 studies in both solid tumors and hematological malignancies, and it was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for pancreatic cancer. CPI-613 is being developed by Cornerstone Pharmaceuticals.
CPI-613 safe and somewhat efficacious for relapsed or refractory leukemia.
Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. The findings, reported by doctors at Wake Forest Baptist Medical Center, are published in the current online edition of the journal Clinical Cancer Research."
This drug is selectively taken up by cancer cells and then shuts down the production of energy in the mitochondria," said Timothy Pardee, M.D., Ph.D., director of leukemia translational research at Wake Forest Baptist and principal investigator of the trial. "This is the first drug to inhibit mitochondria in this way and if it proves effective in further clinical trials, it will open up a whole new approach to fighting cancer."
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|